Jun 30, 2025, 12:38

DoD FY25 Melanoma Research Program Melanoma Academy Scholar Award

Adds independent, early-career melanoma investigators (“Scholars”) to the virtual Melanoma Academy for up to 3 years of career development and research support, fostering a collaborative network of melanoma researchers.

Eligibility Criteria:

Scholar (PI): Independent investigator no more than 7 years from first faculty-level appointment; must have independent laboratory space confirmed by the institution; may hold tenure-track or non-tenure positions.
Restrictions: Mentored positions (e.g., postdocs, clinical fellows) are not eligible as Scholars; if funded, Scholar must not hold another career-development award concurrently.
Career Guide: Each Scholar designates an established melanoma researcher (Associate Professor or higher) as Career Guide, with a strong funding/publication record and commitment to mentoring.

Funding Details:

Total Pool: Approximately 1.54 USD million to fund ~2 awards
Award Cap: Up to 770,000 USD total costs per award over a maximum 3-year period
Period of Performance: Awards made by September 30, 2026; FY25 funds expire September 30, 2031
Use of Funds: Direct and indirect costs per negotiated rates; salary support, supplies, travel (including Academy workshops and one scientific meeting per year), virtual-academy infrastructure; no clinical trial or tuition costs.

Deadlines:

Letter of Intent (Pre-Application): September 10, 2025, by 5:00 p.m. ET
Full Application Submission: October 1, 2025, by 11:59 p.m. ET
End of Verification Period: October 7, 2025, by 5:00 p.m. ET
Peer Review: December 2025
Programmatic Review: February 2026

Where to Go for Further Information & Application:

eBRAP Portal (intramural & pre-application).
Guidelines.
Grants.gov Workspace (extramural full application): search Funding Opportunity Number HT942525MRPMASA.

cancer career development CDMRP collaborative research DoD Early Career independent-research leadership-award Melanoma Melanoma-Academy Melanoma-Academy-Scholar mentorship OncoDaily Oncology virtual-academy

ESMO GI 2025 Highlights: OrigAMI-1 Trial on Amivantamab Rechallenge in mCRC

FDA Oncology News: June 2025 Updates

25 Posts Not To Miss From MASCC 2025

Hagop Kantarjian: A legend is Stepping Down

Rahul Banerjee: Excellent News - FDA Eliminates REMS Across CAR-T Products for US Patients